[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY, European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group: Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res; 2009 Jul 1;69(13):5383-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphopenia is frequent in advanced cancers and predicts the toxicity of chemotherapy.
  • Its prognostic value for survival was analyzed in three databases of previously reported prospective multicenter studies: (a) FEC chemotherapy in metastatic breast carcinoma;.
  • (b) CYVADIC in advanced soft tissue sarcoma (European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group 62791); and (c) prospective, consecutive phase III studies of aggressive diffuse large-cell non-Hodgkin's lymphomas conducted at Centre Léon Bérard between 1987 and 1993.
  • The incidence of lymphopenia of <1,000/microL before treatment was constant among the series: 25%, 24%, and 27%, respectively.
  • Lymphopenia was significantly more frequent (P < 0.05) in metastatic breast cancer patients with performance status (PS) of >1, non-Hodgkin's lymphoma patients with international prognostic index (IPI) of > 0, and advanced soft tissue sarcoma and metastatic breast cancer patients with bone metastases.
  • Inunivariate analysis, lymphopenia of <1,000/microL significantly correlated to overall survival in patients with metastatic breast cancer (median, 10 versus 14 mo; P < 0.0001), advanced soft tissue sarcoma (median, 5 versus 10 months; P < 0.01), and non-Hodgkin lymphoma (median, 11 versus 94 months; P < 0.0001).
  • In multivariate analysis (Cox model), lymphopenia was an independent prognostic factor for overall survival in metastatic breast cancer [RR (relative risk), 1.8; 95% CI (confidence interval), 1.3-2.4] along with liver metastases and PS; in advanced soft tissue sarcoma (RR, 1.46; 95% CI, 1.0-2.1) along with liver metastases, lung metastases, and PS; and in non-Hodgkin's lymphoma (RR, 1.48; 95% CI, 1.03-2.1) along with IPI.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):181-6 [12610500.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2294-9 [12411295.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4235-8 [14615453.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):710-20 [15146561.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):341-53 [15172354.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2371-8 [15197198.001]
  • [Cites] Cancer. 1970 Jan;25(1):135-40 [5410303.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):126-30 [6850535.001]
  • [Cites] Cancer. 1984 May 1;53(9):1825-32 [6367947.001]
  • [Cites] Stat Med. 1985 Jan-Mar;4(1):39-46 [3857702.001]
  • [Cites] Stat Med. 1986 Jul-Aug;5(4):303-17 [3764222.001]
  • [Cites] Bull Cancer. 1990;77(9):941-7 [2224167.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Eur J Cancer. 1994;30A(3):321-4 [8204352.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):575-82 [7884418.001]
  • [Cites] Nat Med. 1996 Mar;2(3):317-22 [8612231.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):636-43 [8636781.001]
  • [Cites] Stat Med. 1995 Dec 15;14(23):2581-98 [8746890.001]
  • [Cites] Nat Med. 1996 Dec;2(12):1361-6 [8946836.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5499-505 [8968107.001]
  • [Cites] Blood. 1998 Jul 15;92(2):405-10 [9657738.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1263-73 [10389908.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Leuk Lymphoma. 1999 Aug;34(5-6):519-27 [10492075.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2675-80 [15503313.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1238-43 [16227988.001]
  • [Cites] Cytokine. 2006 Feb 7;33(3):145-9 [16524740.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2855-62 [16357322.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):1066-70 [16552441.001]
  • [Cites] Pediatr Hematol Oncol. 2006 Mar;23(2):143-51 [16651243.001]
  • [Cites] J Immunother. 2006 May-Jun;29(3):313-9 [16699374.001]
  • [Cites] Semin Hematol. 2006 Oct;43(4):213-20 [17027655.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2698-705 [17063500.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3317-22 [1596890.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1732-40 [17389336.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1209-15 [17496307.001]
  • [Cites] Invest New Drugs. 2010 Feb;28(1):76-82 [19205623.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):168-72 [17060489.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2840-6 [10561360.001]
  • [Cites] Nature. 1999 Nov 18;402(6759):255-62 [10580495.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):947s-957s [11300496.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):816-22 [11556830.001]
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):46-53 [11905837.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 12):1-3 [12170444.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2553-62 [12171883.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):719-27 [12473512.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):64-9 [12504660.001]
  • [Cites] Am J Hematol. 2003 Aug;73(4):263-6 [12879430.001]
  • (PMID = 19549917.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA011488-38; United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 5U10 CA011488-38; United States / NCI NIH HHS / CA / U10 CA011488-38
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS115478; NLM/ PMC2775079
  •  go-up   go-down


2. Marotta D, Sgambato A, Cerciello S, Magarelli N, Martini M, Larocca LM, Maccauro G: Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature. World J Surg Oncol; 2008;6:111
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature.
  • Muscle, bone, and joints are involved by septic arthritis, myopathies and neoplasms.
  • HIV-related neoplastic processes that affect the musculoskeletal system include Kaposi's sarcoma and non-Hodgkin's lymphoma, the latter being mainly localized at lower extremities, spine and skull.
  • The patient decided to continue her pregnancy and to not undergo any diagnostic procedure and treatment.
  • A final diagnosis of diffuse large B-cell lymphoma was made.
  • The patient underwent postoperative chemotherapy.
  • CONCLUSION: In this report, we present a case of diffuse large B-cell lymphoma localized in the soft tissue of the shoulder in a HIV infected patient.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Pregnancy Complications, Neoplastic / pathology. Pregnancy Outcome. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. HIV Infections / diagnosis. HIV Infections / drug therapy. Humans. Immunohistochemistry. Pregnancy. Risk Assessment. Shoulder. Surgical Procedures, Operative / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S82-5 [12734486.001]
  • [Cites] Radiology. 1980 Feb;134(2):521-3 [7352243.001]
  • [Cites] Am J Surg Pathol. 1987 May;11(5):359-66 [3578646.001]
  • [Cites] Br J Radiol. 1989 Jan;62(733):81 [2914198.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):455-9 [7790558.001]
  • [Cites] Bol Asoc Med P R. 1995 Oct-Dec;87(10-12):158-61 [8924158.001]
  • [Cites] Crit Rev Diagn Imaging. 1996 Sep;37(4):305-47 [8894398.001]
  • [Cites] Clin Radiol. 1997 Mar;52(3):203-12 [9091255.001]
  • [Cites] Radiol Clin North Am. 1997 Sep;35(5):1167-89 [9298091.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1998 Feb;27(2):128-34 [9506198.001]
  • [Cites] Semin Ultrasound CT MR. 1998 Apr;19(2):200-8 [9567324.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):88-96 [9888708.001]
  • [Cites] Clin Orthop Relat Res. 1999 Mar;(360):221-30 [10101328.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):329-32 [16321866.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Leukemia. 2007 Feb;21(2):207-14 [17170731.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1443-5 [17515361.001]
  • [Cites] J Am Acad Orthop Surg. 2002 Sep-Oct;10(5):312-20 [12374482.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2002 Sep;88(5):518-21 [12399719.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2405-7 [12613532.001]
  • [Cites] Skeletal Radiol. 2004 Jun;33(6):311-20 [15127244.001]
  • (PMID = 18939988.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


3. Olnes MJ, Nicol T, Duncan M, Bohlman M, Erlich R: Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy. Leuk Lymphoma; 2002 Apr;43(4):817-21
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy.
  • Interdigitating dendritic cell sarcoma (IDCS) is an aggressive neoplasm of which fewer than 25 cases have been reported in the world literature.
  • Patients with this malignancy have been treated with chemotherapy regimens used against non-Hodgkin's lymphomas.
  • Staging of the tumor with CT scan, PET scan, and bone marrow biopsy demonstrated inguinal and abdominal lymphadenopathies, a large mass encasing the small bowel, and extensive liver infiltration.
  • Morphologic and cytochemical analysis of biopsies from the abdominal mass and inguinal node were consistent with a diagnosis of IDCS, and immunohistochemical stains of the lymph node were positive for CLA, Kp-1, S-100, while negative for CD1a, CD3, CD20, CKER, and HMB45.
  • Treatment of this patient with ABVD chemotherapy resulted in rapid clinical improvement with a marked decrease in tumor burden after two cycles of ABVD, and a complete response after six cycles of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dendritic Cells / pathology. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12153170.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


Advertisement
4. Khalid S, Adil SN, Vaziri IA: Granulocytic sarcoma in the absence of acute myeloid leukemia: a case report. Indian J Pathol Microbiol; 2007 Jan;50(1):88-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma in the absence of acute myeloid leukemia: a case report.
  • Granulocytic sarcoma is an extramedullary tumor composed of immature granulocytic precursor cells.
  • The most common sites of presentation are bone, periosteum, soft tissue, lymph node, skin, and infrequently small intestine.
  • It can occur without blood or bone marrow manifestations of leukemia and in this case, the diagnosis is difficult.
  • Our patient was initially diagnosed as a case of T-cell non Hodgkin's lymphoma and received one cycle of CHOP with only transient improvement in his symptoms.
  • Subsequently, his biopsy slides were reviewed at our centre and were reported as granulocytic sarcoma.
  • [MeSH-major] Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy. Bone Marrow / pathology. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Histocytochemistry. Humans. Leukemia, Myeloid, Acute / complications. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Male. Neoplasms. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474271.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


5. Pant V, Jambhekar NA, Madur B, Shet TM, Agarwal M, Puri A, Gujral S, Banavali M, Arora B: Anaplastic large cell lymphoma (ALCL) presenting as primary bone and soft tissue sarcoma--a study of 12 cases. Indian J Pathol Microbiol; 2007 Apr;50(2):303-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma (ALCL) presenting as primary bone and soft tissue sarcoma--a study of 12 cases.
  • This study highlights the rare presentation of anaplastic large cell lymphoma as primary bone and soft tissue tumour.
  • Clinical impression was non Hodgkin's lymphoma in 4 cases, sarcoma in 6 (osteosarcoma-2, Ewing's/primitive neuroectodermal tumour-1, and sarcoma NOS-3), and tuberculosis of thoracic spine in 1 and the last case involving the rib had a differential diagnosis of tuberculosis and NHL.
  • The pleomorphic cytomorphology ofALCL leads to confusion with the more frequent bone and soft tissue sarcomas affecting the musculoskeletal system.
  • This alone will lead to an accurate recognition of ALCL and the appropriate chemotherapy.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Activin Receptors, Type II / metabolism. Adolescent. Adult. Antigens, CD30 / metabolism. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male


6. Colella G, Tirelli A, Capone R, Rubini C, Guastafierro S: Myeloid sarcoma occurring in the maxillary gingiva: a case without leukemic manifestations. Int J Hematol; 2005 Feb;81(2):138-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma occurring in the maxillary gingiva: a case without leukemic manifestations.
  • Myeloid sarcoma (MS) is a localized extramedullary mass of immature granulocytic cells that usually occurs in patients with acute myeloid leukemia (AML) or myeloproliferative disorders.
  • It may rarely precede peripheral blood or bone marrow involvement, presenting a diagnostic challenge.
  • The histologic specimen was first interpreted as non-Hodgkin's lymphoma.
  • The correct diagnosis was reached after extensive immunohistologic studies.
  • Induction therapy with FLAND (fludarabine, Ara-C, mitoxantrone, and dexamethasone) was started, but the patient did not achieve a remission.
  • The present case indicates the importance of a correct initial diagnosis for adequate therapy, which is often delayed because of a high misdiagnosis rate.
  • If the MS is treated without intensive chemotherapy for AML as soon as possible, the prognosis will be poor.
  • [MeSH-major] Gingival Neoplasms / pathology. Maxillary Neoplasms / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Diagnostic Errors. Fatal Outcome. Female. Humans. Immunophenotyping. Magnetic Resonance Imaging. Middle Aged. Pleural Effusion, Malignant

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] J Oral Maxillofac Surg. 2000 Sep;58(9):1055-8 [10981989.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):1011-9 [8372941.001]
  • [Cites] Histopathology. 1999 May;34(5):391-8 [10231412.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Feb;7(1):275-92 [8449862.001]
  • [Cites] Int J Surg Pathol. 2003 Oct;11(4):271-82 [14615822.001]
  • [Cites] Pediatr Hematol Oncol. 1986;3(3):293-6 [3153242.001]
  • [Cites] Arch Dermatol. 1990 May;126(5):653-6 [2334186.001]
  • [Cites] Arch Pathol Lab Med. 2001 Nov;125(11):1448-52 [11698000.001]
  • (PMID = 15765782.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. D'Costa GF, Hastak MS, Patil YV: Granulocytic sarcoma of breast: an aleukemic presentation. Indian J Med Sci; 2007 Mar;61(3):152-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of breast: an aleukemic presentation.
  • Granulocytic sarcoma is a rare extramedullary tumor composed of immature myeloid cells.
  • The breast is an uncommon site of presentation and requires a high index of suspicion for diagnosis.
  • A peripheral smear and bone marrow examination at that time was normal.
  • An H and E diagnosis of lobular carcinoma vs. non-Hodgkin's lymphoma was entertained.
  • Immunostains, however, revealed myeloperoxidase, naphthol AS-D chloroacetate esterase and CD43 positivity, indicating a diagnosis of granulocytic sarcoma.
  • It appears that early initiation of systemic AML-type chemotherapy is beneficial and may delay or avert the development of AML in bone marrow and blood.
  • Eight months later, the patient presented with an orbital mass; bone marrow and peripheral smear involvement by AML.
  • [MeSH-major] Breast Neoplasms / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / diagnosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337816.001).
  • [ISSN] 0019-5359
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD43; 0 / Naphthols; 35245-26-2 / naphthol AS-D chloroacetate; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


8. Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M, Bicciato S, Nico B, Ribatti D, Dammacco F, Corradini P: Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol; 2005 Aug 10;23(23):5334-46
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
  • PATIENTS AND METHODS: The expression of key angiogenic genes was studied in bone marrow endothelial cells (ECs) of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies unattributed/unassociated (MG[u]), diffuse large B-cell non-Hodgkin's lymphoma, in a Kaposi's sarcoma (KS) cell line, and in healthy human umbilical vein ECs (HUVECs) following exposure to therapeutic doses of thalidomide.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Endothelium, Vascular / drug effects. Fibroblast Growth Factor 2 / genetics. Hepatocyte Growth Factor / genetics. Multiple Myeloma / metabolism. Thalidomide / pharmacology. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / pathology. Cells, Cultured. Culture Media, Conditioned. Down-Regulation. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Profiling. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Middle Aged. Paraproteinemias / drug therapy. Paraproteinemias / genetics. Paraproteinemias / metabolism. RNA, Messenger / metabolism. RNA, Neoplasm / metabolism. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / genetics. Sarcoma, Kaposi / metabolism. Umbilical Veins / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15939924.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Culture Media, Conditioned; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; 4Z8R6ORS6L / Thalidomide; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


9. Guérin S, Hawkins M, Shamsaldin A, Guibout C, Diallo I, Oberlin O, Brugières L, de Vathaire F: Treatment-adjusted predisposition to second malignant neoplasms after a solid cancer in childhood: a case-control study. J Clin Oncol; 2007 Jul 1;25(19):2833-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-adjusted predisposition to second malignant neoplasms after a solid cancer in childhood: a case-control study.
  • PURPOSE: Previous therapy, genetic susceptibility, and the type of first malignant neoplasm (FMN) are known to be associated with the risk of second malignant neoplasm (SMN) among patients treated for a childhood cancer.
  • One hundred forty-six patients with an SMN and 417 controls were matched for sex, age at FMN, chemotherapy, radiotherapy, the local radiation dose received at the site of SMN for patient cases and at the same site for the matched controls, and follow-up.
  • RESULTS: A significantly increased risk of developing any SMN was observed after Hodgkin's lymphoma, retinoblastoma, malignant bone tumor, soft tissue sarcoma (STS), and germ cell tumor as FMN, after adjustment for chemotherapy and family cancer syndrome.
  • No significant risk of developing a carcinoma was observed among patients who had developed Hodgkin's lymphoma as FMN.
  • A significantly increased risk of developing a sarcoma was observed among patients who had developed a retinoblastoma (adjusted odds ratio [ORa] = 7.5; 95% CI, 1.2 to 46), a malignant bone tumor (ORa = 13.3; 95% CI, 1.5 to 117), an STS (ORa = 4.8; 95% CI, 1.3 to 18), or a carcinoma (ORa = 9.4; 95% CI, 1.1 to 82) as FMN.
  • CONCLUSION: Survivors of Hodgkin's lymphoma, retinoblastoma, malignant bone tumor, STS, and germ cell tumor should receive close surveillance because they are at increased risk of developing any SMN.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms / drug therapy. Neoplasms / radiotherapy. Neoplasms, Germ Cell and Embryonal / therapy. Neoplasms, Second Primary / etiology. Retinoblastoma / therapy. Sarcoma / therapy


10. Koshy M, Paulino AC, Mai WY, Teh BS: Radiation-induced osteosarcomas in the pediatric population. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1169-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to perform a comprehensive literature review and analysis of reported cases dealing with R-OS in the pediatric population to identify the characteristics, prognostic factors, optimal treatment modalities, and overall survival of these patients.
  • Eligibility criteria included patients <21 years of age at the diagnosis of the primary cancer, cases satisfying the modified Cahan criteria, and information on treatment outcome.
  • Factors analyzed included the type of primary cancer treated with RT, the radiation dose and beam energy, the latency period between RT and the development of R-OS, and the treatment, follow-up, and final outcome of R-OS.
  • RESULTS: The series included 109 patients with a median age at the diagnosis of primary cancer of 6 years (range, 0.08-21 years).
  • The most common tumors treated with RT were Ewing's sarcoma (23.9%), rhabdomyosarcoma (17.4%), retinoblastoma (12.8%), Hodgkin's disease (9.2%), brain tumor (8.3%), and Wilms' tumor (6.4%).
  • The median radiation dose was 47 Gy (range, 15-145 Gy).
  • The median follow-up after diagnosis of R-OS was 18 months (1-172 months).
  • Variables, including age at RT, primary site, type of tumor treated with RT, total radiation dose, and latency period did not have a significant effect on survival.
  • The 5-year cause-specific and overall survival rate for patients who received treatment for R-OS involving chemotherapy alone, surgery alone, and surgery plus chemotherapy was 17.3% and 17.3%, 56.6% and 50.3%, and 71.0% and 68.3%, respectively (p < 0.0001, log-rank test).
  • CONCLUSION: The type of treatment for R-OS was the most significant factor for cause-specific and overall survival.
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / radiotherapy. Child. Child, Preschool. Female. Hodgkin Disease / radiotherapy. Humans. Infant. Infant, Newborn. Male. Retinoblastoma / radiotherapy. Rhabdomyosarcoma / radiotherapy. Sarcoma, Ewing / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054775.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


11. Ludwig K: [Musculoskeletal lymphomas]. Radiologe; 2002 Dec;42(12):988-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary lymphomas of bone or skeletal muscle are rare entities.
  • The most frequent among these diseases are primary non-Hodgkin's lymphomas of bone.
  • They account for 3-5% of all bone tumors and 5% of all primary extranodal non-Hodgkin's lymphomas.
  • Primary manifestations of Hodgkin's disease in bone or skeletal muscle are rarities.
  • Primary non-Hodgkin's lymphomas of skeletal muscle are rarities as well.
  • Primary non-Hodgkin's lymphomas of bone can be found in any patient age.
  • The radiographic appearance of these entities resembles other aggressive bone tumors.
  • Their differential diagnosis includes -- depending on the patient's age -- Ewing's sarcoma,malignant fibrous histiocytoma,metastases of small cell tumors and osteomyelitis.Further differential diagnoses are the peripheral primitive neuroectodermal tumor (PNET), osteosarcoma, eosinophilic granuloma and fibrosarcoma.
  • Treatment of primary non-Hodgkin's lymphomas uses combinations of chemotherapy and radiation therapy.
  • Operative treatment is reserved for the treatment of complications.
  • The prognosis of primary non-Hodgkin's lymphomas is reflected by 10-year-survival-rates without recurrence of more than 80% in unifocal manifestations.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Magnetic Resonance Imaging. Muscle Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Bone and Bones / pathology. Humans. Muscle, Skeletal / pathology. Neoplasm Staging. Prognosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12486552.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 0
  •  go-up   go-down


12. Ferrucci PF, Martinoni A, Cocorocchio E, Civelli M, Cinieri S, Cardinale D, Peccatori FA, Lamantia G, Agazzi A, Corsini C, Tealdo F, Fiorentini C, Cipolla CM, Martinelli G: Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. Bone Marrow Transplant; 2000 Jan;25(2):173-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy.
  • Peripheral blood progenitor cell reinfusion (PBPC) in patients undergoing high-dose chemotherapy (HDC) for poor prognosis malignancies, has been described as causing possible acute gastrointestinal (nausea, vomiting), allergic (oedema, bronchospasm, anaphyl- axis), renal (proteinuria, haematuria) and/or cardiovascular (hypotension, arrhythmia, conduction disturbances, transient ischaemic phenomena) toxicities.
  • To establish the clinical relevance of these observations and the possible relationship with different HDC regimens used, we performed a clinical and instrumental evaluation on 33 patients with advanced breast cancer, non-Hodgkin's lymphoma, Hodgkin's disease, relapsed ovarian cancer, Ewing's sarcoma, extragonadal germinal tumour and small cell lung cancer.
  • To evaluate cardiovascular function, we continuously monitored 12-lead ECGs, with arterial pressure (AP) measurements every 5 min from the beginning of the procedure to 15 min after the reinfusion ended.
  • We did not observe any significant differences between basal and subsequent steps in AP, heart rate, PQ and QTc time, P wave and QRS complex duration or P wave and QRS electrical axes.
  • No patient showed any ST-T tract pathological abnormality, but one patient developed a transient ectopic atrial rhythm, without any haemodynamic disfunction and with spontaneous reversion to sinus rhythm.
  • In one patient a tonic-clonic seizure occurred during a vomiting episode, but no patient developed allergic or renal toxicities.
  • We conclude that PBPC reinfusion, if managed according to the procedure we propose in patients without organic impairment, is a safe procedure not associated either with increased risk of acute arrhythmias or ischaemic or significant systemic acute toxicities.
  • Bone Marrow Transplantation (2000) 25, 173-177.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Bone Marrow Transplant. 2002 Mar;29(6):544 [11960281.001]
  • (PMID = 10673676.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


13. Kanaev SV, Novikov SN, Zhukova LA, Malinin AP, Kolygin BA: [Role of bone marrow scintigraphy in defining the therapeutic approach for some malignant tumors in children] . Vopr Onkol; 2000;46(4):419-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of bone marrow scintigraphy in defining the therapeutic approach for some malignant tumors in children] .
  • The data on scintigraphic examinations of the bone marrow (BM) carried out in 76 patients, aged 2-16, are evaluated.
  • Metastases to BM were detected in 6 out of 28 (21%) patients with Hodgkin's disease.
  • Scintigraphic evidence played a role in working out treatment modalities in 4 cases.
  • Metastatic foci located outside primary tumor were detected in 3 out of 26 (11.5%) patients with Ewing's sarcoma and scintigraphic findings were considered in all 3 cases when scope of radiotherapy and chemotherapy intensity were elaborated.
  • [MeSH-major] Bone Marrow Neoplasms / radionuclide imaging. Bone Marrow Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Hodgkin Disease / radionuclide imaging. Hodgkin Disease / therapy. Humans. Infant. Male. Neuroblastoma / radionuclide imaging. Neuroblastoma / therapy. Sarcoma, Ewing / radionuclide imaging. Sarcoma, Ewing / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11147416.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


14. Gupta S, Kanodia AK: Biological response modifiers in cancer therapy. Natl Med J India; 2002 Jul-Aug;15(4):202-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological response modifiers in cancer therapy.
  • Monoclonal antibodies directed against tumour-specific agents have been approved for the treatment of breast cancer (trastuzumab), non-Hodgkin's lymphoma (rituximab) and for the diagnosis of certain cancers (oncoscint).
  • Interferons are indicated for the treatment of certain leukaemias and Kaposi's sarcoma to inhibit tumour proliferation and angiogenesis.
  • Haematopoletic growth factors are often combined with chemotherapy and radiotherapy to restore bone marrow function and treat complications such as infection and bleeding.
  • Various anticancer vaccines are being developed using tumour cells, carbohydrates, peptides and heat-shock proteins as antigens.
  • [MeSH-major] Immunologic Factors / therapeutic use. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12296474.001).
  • [ISSN] 0970-258X
  • [Journal-full-title] The National medical journal of India
  • [ISO-abbreviation] Natl Med J India
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Immunologic Factors
  • [Number-of-references] 80
  •  go-up   go-down


15. Tassinari D, Poggi B, Nicoletti S, Fantini M, Tamburini E, Possenti C, Sartori S: Zoledronic acid treatment at home: safety data from an observational prospective trial. J Palliat Med; 2007 Apr;10(2):352-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid treatment at home: safety data from an observational prospective trial.
  • BACKGROUND: To prospectively assess feasibility, side effects, and safety of a home treatment with zoledronic acid in patients with bone metastases confined to home.
  • PATIENTS AND METHODS: Forty-two patients with bone metastases (15 males and 27 females; mean age, 72 years; range, 48-86), confined to home because of functional impairment or low performance status, were enrolled into the trial.
  • Primary end point of this observational trial was the safety assessment of the treatment at home; secondary end points were the clinical assessment of the time to treatment discontinuation and the definition of a pattern of patients who could benefit by a home treatment with intravenous bisphosphonates.
  • RESULTS: Nineteen patients had breast cancer; 7, multiple myeloma; 5, non-small-cell lung cancer; 4, renal cancer; 4, prostate cancer; 1, thyroid cancer; 1 non-Hodgkin's lymphoma; and 1 soft tissue sarcoma.
  • On the whole, 220 home treatments were administered in 3 years, with a median of 4 administrations per patient (range, 1-28).
  • Median time to treatment discontinuation was 130 days.
  • The treatment was interrupted for worsening of the performance status in 30 patients (71.4%), length of the treatment greater than 24 months in 2 patients (4.8%), hypocalcemia in 1 patient (2.4%), renal failure in 1 patient (2.4%).
  • No difference in median time to treatment discontinuation was observed among patients with breast cancer, multiple myeloma, or other tumors in univariate analysis.
  • Multivariate analysis showed no prognostic significance for kind of tumor, age at the time of entering the trial, gender, and number of extraosseous sites of disease.
  • No acute major side effects were observed during the treatment, and the treatment had to be interrupted for side effects in 2 patients (4.8%).
  • One patient had jaw osteonecrosis some months after the treatment was stopped.
  • CONCLUSIONS: The home treatment with zoledronic acid seems safe.
  • The appropriate use of biphosphonates in such a new setting needs a criterion to identify the subset of patients with bone metastases confined to home who can really benefit by this treatment.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / pathology. Diphosphonates / therapeutic use. Home Care Services. Imidazoles / therapeutic use. Multiple Myeloma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Creatinine / blood. Drug-Related Side Effects and Adverse Reactions. Feasibility Studies. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Observation. Prospective Studies. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Home Care Services.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472506.001).
  • [ISSN] 1096-6218
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; AYI8EX34EU / Creatinine
  •  go-up   go-down


16. Schwartz L: [Survival in adolescents and young adults with cancer in childhood]. Medicina (B Aires); 2001;61(4):401-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis were: retinoblastoma: 24, nephroblastoma: 19, Hodgkin's disease: 14, sarcoma: 12, neuroblastoma: 11, non-Hodgkin-lymphoma: 11, Langerhans cell histiocytosis: 5 (multifocal bone lesions: 4, Hand-Schüller-Christian disease: 1), gonadal germ-cell tumors: 4, osteosarcoma: 2, Ewing sarcoma: 2.
  • The treatment consisted of: surgery + chemotherapy + radiotherapy: 52, chemotherapy + radiotherapy: 18, surgery + chemotherapy: 13, surgery + radiotherapy: 7 surgery: 7 and chemotherapy: 7.
  • It is concluded that a constant follow-up and evaluation of these patients is necessary in order to give them the opportunity of therapeutic solutions and psychosocial rehabilitations.
  • [MeSH-major] Neoplasms / therapy. Survivors
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Neoplasms, Second Primary / therapy. Survival Analysis

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11563167.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


17. Marquez J, Restrepo CS, Candia L, Berman A, Espinoza LR: Human immunodeficiency virus-associated rheumatic disorders in the HAART era. J Rheumatol; 2004 Apr;31(4):741-6
HIV InSite. treatment guidelines - Non-ARV Adverse Events .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To define the frequency and characteristics of human immunodeficiency virus (HIV)-associated rheumatic manifestations in patients receiving highly active antiretroviral therapy (HAART) referred to a rheumatology clinic.
  • Diagnosis of HIV infection was performed by ELISA and confirmed by Western blot, and all HIV patients were classified according to the US Centers for Disease Control criteria.
  • The group included 40 (53%) heterosexuals, 30 (40%) intravenous drugs users, 9 (12%) homosexuals, 3 (4%) who had received blood transfusion, and 2 (2.6%) with unknown risk factors.
  • Mutifocal bone non-Hodgkin's lymphoma was present in 7 (9.3%) and Kaposis's sarcoma of bone in 2 (2.6%) patients.
  • Hypertrophic osteoarthropathy in 3 (4%) and aseptic bone necrosis of multiple bones was seen in 3 (4%) patients.
  • [MeSH-major] Anti-HIV Agents. Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. Rheumatic Diseases / virology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15088301.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down






Advertisement